Cancer                            Multiple Sclerosis
Clinical Studies
Scientific Research
Inventor                         The Team
FAQ                               In The News

Shreis-Scalene Sciences
11516 Darnestown Rd. Gaithersburg,MD 20878
Tel : (001)301-926-0566
Fax : (001)301-926-2925
email : Shré


Prof. Meena Augustus Ph.D.

Meena Augustus is Co-Founder, CEO & CSO for Shréis-Scalene Sciences LLC and Shreis Scalene Therapeutics LLC (N. & S. America Mexico & the Caribbean), located in Gaithersburg, Maryland and SSS-Canada Inc. in Montreal (CA) (  SSS is focused on bringing to the US and global markets, a patented CE and CAMCDAS certified innovative therapeutic device, the Cytotron® that deploys non-invasive and non-ionizing rotational field quantum magnetic resonance (RFQMR) for the treatment of  all solid tumors, musculoskeletal diseases like Osteoarthritis and Neurodegenerative diseases like Multiple Sclerosis, Alzheimer’s, Stroke etc.  Under her scientific guidance & fund raising efforts with the President & COO, a project to treat recurrent drug/radiation resistant Glioblastoma with the CYTOTRON® was awarded a quarter million USD grant, under the U.S. Government’s Qualifying Therapeutic Discovery Project (“QTDP”) program, in 2010. The Cytotron also has broad applications in tissue engineering and multi organ wound healing. An innovative drug delivery extension of this platform technology has been leveraged in a unique drug/device pairing approach with cancer chemotherapeutics, which Shreis Scalene Therapeutics LLC is offering. As Co-Founder, VP & CSO of Shreis Scalene Cardiotech, Dr. Augustus is pursuing clinical collaborations for a CE marked, non-invasive, diagnostic cardiovascular device-the Hemoseis 256 that is also being introduced in the N. & S. American continent.  In Oct 2010, a renewable energy company, Shreis Scalene Greenergy LLC ( was also registered by Shreis founders.

Meena Augustus is a cancer geneticist by background. She co-founded Avalon Pharmaceuticals Inc.,-a biotech company, located in Germantown, MD, that pioneered revolutionary biomarker-driven drug and target discovery in cancer. She was integral to the management team that raised seed capital and 80M in private equity in the early years of the company, and saw Avalon through an IPO in Nov 2005. As Senior Scientific Director, she oversaw the efforts of the Molecular Genetics and Oncology group since the company’s inception in 2000 and was instrumental to the development of Avalon’s Amplicon and Biorepository databases and drug response biomarker signatures.  She also oversaw Strategic Scientific Alliances for Avalon, between 2003-2006, initiating and establishing several key scientific, academic and clinical collaborations for the company, both domestic and international.  Dr. Augustus’ independent US-based company, CanCure Consulting LLC, ( offered Pharmaceutical R &D consulting services to the Federal Government-National Cancer Institute’s Nanotechnology Program, helping to accelerate the development of cancer nano-therapeutics, for three consecutive years (2007-2010). During her career, Dr. Augustus has served in premier research institutions in India, Germany, France and U.S and has been the recipient of the prestigious German Academic Exchange Service (DAAD) in 1984 to pursue her commitment to the study of cancer genetics and clinical oncology in Erlangen, Germany. She and was awarded Alexander von Humboldt Fellowship in 1994 which could not be utilized due to conflict with a diplomatic posting to Washington DC at the same time. For 18 years she was a member of the oncology faculty in an UICC-affiliated, 250-bed Comprehensive Cancer Research, Treatment and Teaching Hospital in Bangalore, India, eventually serving as Professor and Head, Department of Cell-biology & Pathology. During that time, she played a key role in a large scale WHO-sponsored cancer detection and screening program in Karnataka, India and was a co-investigator in a multi-institutional Indo-US (NCI-sponsored) study on the molecular characterization of lymphoid neoplasia.  She accompanied her husband on his diplomatic assignment to the Embassy of India in Washington DC, from 1994-1998 combining it with a sabbatical as a Special Volunteer with the Fogarty International Center, at the NIH in Bethesda, USA.  Dr. Augustus has held a visiting scientist position at Human Genome Sciences Inc., in Rockville, MD where she individually mapped more than 100 new human genes to their chromosomal locations. She also served as a consultant at the Center for Prostate Disease Research (USUHS/Henry M. Jackson Foundation for the Advancement of Military Medicine) in Rockville, MD, where she pioneered a study on the molecular cytogenetic analysis of prostate cancer. During 1997-1999, Dr. Augustus was a visiting scientist in the Lymphoma Biology Section-Pediatric Branch and the Cancer Genetics Group (NCI/NIH), and the Genome Technology Branch (NHGRI-NIH) in Bethesda, MD.  She played a key role in the design and development of the NCI and NCBI SKY/CGH Interactive Online (Cytogenetic) Database, a public resource that will enable the compilation and analysis of chromosome aberrations in cancer, both human and mouse (

She is an active AACR and ASCO member and served on the scientific advisory board of the BioIT Coalition in Washington DC ( She was Executive Partner with HealthCare Global (HCG-Oncology) Enterprises Ltd., and Triesta Sciences Inc. (March ‘06-March ’09) located in Bangalore, India, (, serving more than 15000 cancer patients annually. As Scientific Advisor to Triesta-a reference molecular oncology Unit of HCG Dr. Augustus coordinated, designed and oversaw biomarker driven contracts research & outsourced clinical trials to India, with some of the  top 10 large pharma companies.

Prof. Augustus earned an M.S. in Zoology in 1974 and a Ph.D. in Human Genetics in 1979, from India. She has several biotech related patents and a significant publication record of original articles in peer reviewed journals, text book chapters and invited talks in key scientific and industrial forums.



In the NEWS 






Engineering Solutions to Human Problems